# Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis

> **NCT02060305** · PHASE1 · TERMINATED · sponsor: **National Taiwan University Hospital** · enrollment: 5 (actual)

## Conditions studied

- Hemophilia
- Synovitis

## Interventions

- **DRUG:** Bevacizumab intra-articular injection

## Key facts

- **NCT ID:** NCT02060305
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Very slow enrollment
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060305, "Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02060305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*